Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 13/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23224045 | 1.00 | SLC10A1 (0.52) | SLC10A1MAPK1ALDH1A1LMNAMAPT | |
| SCHEMBL23223989 | 0.90 | SLC10A1 (0.55) | SLC10A1MAPK1 | |
| SCHEMBL23223990 | 0.90 | SLC10A1 (0.55) | SLC10A1MAPK1 | |
| SCHEMBL28634542 | 0.90 | SLC10A1 (0.51) | SLC10A1MAPK1ALDH1A1 | |
| SCHEMBL22307696 | 0.90 | SLC10A1 (0.51) | SLC10A1MAPK1ALDH1A1 | |
| SCHEMBL22307721 | 0.90 | SLC10A1 (0.51) | SLC10A1MAPK1ALDH1A1 | |
| SCHEMBL22307697 | 0.89 | SLC10A1 (0.54) | SLC10A1MAPK1KMT2A | |
| SCHEMBL23224036 | 0.89 | SLC10A1 (0.54) | SLC10A1MAPK1KMT2A | |
| SCHEMBL22307722 | 0.89 | SLC10A1 (0.54) | SLC10A1MAPK1KMT2A | |
| SCHEMBL28623186 | 0.84 | SLC10A1 (0.61) | SLC10A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204510-A1 | 2,3-DIHYDRO-1H-PYRROLIZINE-7-FORMAMIDE DERIVATIVE AND APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-30 | — | — | US | disclosed |
| EP-3805223-A1 | 2,3-DIHYDRO-1H-PYRROLIZINE-7-FORMAMIDE DERIVATIVE AND APPLICATION THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204510-A1 | 2,3-DIHYDRO-1H-PYRROLIZINE-7-FORMAMIDE DERIVATIVE AND APPLICATION THEREOF | DPYD, EIF2AK2, INF2 | SLC10A1 76/4885MAPK1 3049/4885ALDH1A1 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.